Bibliography
- MASSBERG S, VON ANDRIAN UH: Fingolimod and sphringosine-1-phosphate – modifiers of lymphocyte migration. N. Engl. J. Med. (2006) 355:1088-1091.
- DOGGRELL SA: Natalizumab in multiple sclerosis: proceed with caution? Expert Opin. Pharmacother. (2006) 7:1675-1678.
- BRINKMANN V, DAVIS MD, HEISE CS et al.: The immune modulation FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. (2002) 277:21453-21457.
- FUJINO M, FUNESSHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305:70-77.
- WEBB M, THAM CS, LIN FF et al.: Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. (2004) 153:108-121.
- KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355:1124-1140.
- PRISMS (PREVENTION OFRELAPSES AND DISABILITY BY INTERFERON BETA-1A SUBCUTANEOUSLY INMULTIPLE SCLEROSIS) STUDY GROUP: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498-1504.
- JOHNSON KP, BROOKS BR, FORD CC et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. (2000) 6:255-266.
- POLMAN CH, O’CONNOR RW, HAVRDOVA E et al.: A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:899-910.
- KOYRAKH L, ROMAN MI, BRINKMANN V, WICKMAN K: The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh. Am. J. Transplant (2005) 5:529-536.
- FUJISHIRO J, KUDOU S, IWAI S et al.: Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation (2006) 82:804-812.
- SHIMIZU H, TAKAHASHI M, KANEKO T et al.: KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation (2005) 111:222-229.
- MULGAONKAR S, TEDESCO H, OPPENHEIMER F et al.: FTY720/cyclosporine regimens in de nova renal transplantation: a 1-year dose-finding study. Am. J. Transplant (2006) 6:1848-1857.
- SALVADORI M, BUDDE K, CHARPENTIER B et al.: FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant (2006) 6:2912-2921.
Websites
- http://www.emdicine.com/emerg/topic321.htm Lazoff M: Multiple Sclerosis. Emedicine from WebMD (2007).
- http:www.medscape.com/viewarticle/545804_print Fingolimod effective to 24 months in relapsing MS.